CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.

A new report by Commonwealth Fund ranks all 50 states and the District of Columbia across 50 indicators covering access, quality, outcomes and equity from data collected up to 2023.

Headspace has debuted a virtual therapy service called Therapy by Headspace that blends licensed care with AI support and ...

Many parents said they were afraid of noninvasive ventilation, with some citing inaccurate concerns about ventilation devices.

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and ...

Proposed Medicaid cuts by the House Budget Committee could result in 7.6 million more uninsured Americans and more than ...

Semaglutide appears to reduce the risk of death, heart attack and stroke in adults with type 2 diabetes more effectively than ...

More cases of interstitial lung disease (ILD) in India can be traced back to occupational exposure and other environmental ...

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...